GlassScriptPhysician profile
Sonia Gajula
NPI 1417055989
$4,367.61
in general payments reported to CMS, 2019-2025
32 companies · $2,511 in 2025
The $2,511 reported for 2025 was more than what 80% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154 · 2020: $236 · 2021: $118 · 2022: $36.57 · 2023: $514 · 2024: $798 · 2025: $2,511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,460 · Travel and Lodging: $1,335 · Long Term Medical Supply Or Device Loan: $19.98 · Education: $7.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,459.83 |
| Travel and Lodging | $1,335.44 |
| Long Term Medical Supply Or Device Loan | $19.98 |
| Education | $7.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,738.77 | 2023-2025 | Minimed 780g |
| Corcept Therapeutics | $379.05 | 2019-2024 | Korlym |
| Novo Nordisk INC | $237.71 | 2019-2025 | Rybelsus, Ozempic |
| Abbott Laboratories | $205.91 | 2021-2025 | Freestyle Insulinx, Freestyle Libre 3, Freestyle Libre 2 |
| Insulet Corporation | $183.26 | 2023-2025 | Omnipod |
| Ascendis Pharma Endocrinology INC | $171.82 | 2025 | Yorvipath |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.23 | 2020-2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $142.31 | 2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $139.88 | 2020-2024 | Lokelma |
| Lilly USA, LLC | $108.85 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Harmony Biosciences LLC | $101.48 | 2020 | |
| Amryt Pharma Holdings LTD | $70.25 | 2023 | Mycapssa |
| Novartis Pharmaceuticals Corporation | $69.22 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $62.35 | 2025 | Zenpep |
| Amgen INC. | $62.35 | 2023-2024 | Evenity, Tepezza, Prolia |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo USA, INC. | $52.73 | 2024-2025 | Xiaflex, Edex, Aveed |
| Kyowa Kirin, INC. | $52.20 | 2024-2025 | Crysvita |
| Beta Bionics, INC. | $51.73 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Janssen Biotech, INC. | $46.59 | 2025 | Simponi Aria, Stelara, Tremfya |
| Recordati_rare_diseases_inc. | $45.22 | 2024 | Isturisa, Signifor Lar |
| Olympus America INC. | $43.16 | 2025 | Itind System |
| Abbvie INC. | $31.55 | 2024 | |
| Alexion Pharmaceuticals, INC. | $28.78 | 2025 | Strensiq |
| Sanofi-Aventis U.S. LLC | $28.34 | 2023 | |
| Radius Health, INC. | $24.45 | 2024 | Tymlos |
| Cycle Pharmaceuticals INC | $23.07 | 2025 | Venxxiva |
| Sumitomo Pharma America, INC. | $19.32 | 2024 | Gemtesa |
| Horizon Therapeutics Plc | $18.17 | 2023 | Tepezza |
| Tandem Diabetes Care, INC. | $17.96 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Amneal Pharmaceuticals LLC | $16.95 | 2024 | Unithroid |
| Xeris Pharmaceuticals, INC. | $16.14 | 2025 | Gvoke Hypopen |
| Dexcom, INC. | $14.81 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonia Gajula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.